Control Bionics Completes Acquisition of US-based Neuro Elite Athletics, Shares Fall Over 3%
MT Newswires Live
Dec 31, 2025
Control Bionics (ASX:CBL) completed the acquisition of 100% of Neuro Elite Athletics on Wednesday, with Control Bionics' US-based unit, Control Bionics Ngage, acquiring the remaining ownership interests in Neuro Elite Athletics, resulting in it becoming a wholly-owned unit of Control Bionics, according to a same-day Australian bourse filing.
The final consideration was $370,028, satisfied via the issue of 8.4 million ordinary fully paid shares in Control Bionics at an issue price of AU$0.0653 per share.
Control Bionics will integrate Neuro Elite Athletics' intellectual property, brand, customers, and operational capabilities into the broader group.
Its shares fell 3% in recent trading on Wednesday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.